Related Experiment Video
Updated: Nov 9, 2025

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
Published on: July 20, 2014
SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma
Abhilash Venugopalan1, Matthew Lynberg2, Constance M Cultraro2
1Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA. abhilash.venugopalan@nih.gov.
Abstract:
Mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain constitutively activate EGFR resulting in lung tumorigenesis. Activated EGFR modulates downstream signaling by altering phosphorylation-driven interactions that promote growth and survival. Secretory carrier membrane proteins (SCAMPs) are a family of transmembrane proteins that regulate recycling of receptor proteins, including EGFR. The potential role of SCAMPs in mutant EGFR function and tumorigenesis has not been elucidated. Using quantitative mass-spectrometry-based phosphoproteomics, we identified SCAMP3 as a target of mutant EGFRs in lung adenocarcinoma and sought to further investigate the role of SCAMP3 in the regulation of lung tumorigenesis. Here we show that activated EGFR, either directly or indirectly phosphorylates SCAMP3 at Y86 and this phosphorylation increases the interaction of SCAMP3 with both wild-type and mutant EGFRs. SCAMP3 knockdown increases lung adenocarcinoma cell survival and increases xenograft tumor growth in vivo, demonstrating a tumor suppressor role of SCAMP3 in lung tumorigenesis. The tumor suppressor function is a result of SCAMP3 promoting EGFR degradation and attenuating MAP kinase signaling pathways. SCAMP3 knockdown also increases multinucleated cells in culture, suggesting that SCAMP3 is required for efficient cytokinesis. The enhanced growth, increased colony formation, reduced EGFR degradation and multinucleation phenotype of SCAMP3-depleted cells were reversed by re-expression of wild-type SCAMP3, but not SCAMP3 Y86F, suggesting that Y86 phosphorylation is critical for SCAMP3 function. Taken together, the results of this study demonstrate that SCAMP3 functions as a novel tumor suppressor in lung cancer by modulating EGFR signaling and cytokinesis that is partly Y86 phosphorylation-dependent.
Insights
Secretory carrier membrane protein 3 (SCAMP3) acts as a tumor suppressor in lung cancer. It regulates epidermal growth factor receptor (EGFR) signaling and cell division, with phosphorylation at Y86 being crucial for its function.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Mutations in epidermal growth factor receptor (EGFR) drive lung tumorigenesis by constitutively activating signaling pathways.
- Secretory carrier membrane proteins (SCAMPs) are involved in receptor recycling, but their role in mutant EGFR signaling and lung cancer is unknown.
Purpose of the Study:
- To investigate the role of SCAMP3 in lung adenocarcinoma.
- To determine if SCAMP3 functions as a tumor suppressor by modulating EGFR signaling.
Main Methods:
- Quantitative mass-spectrometry-based phosphoproteomics to identify SCAMP3 as an EGFR target.
- SCAMP3 knockdown and re-expression experiments in lung adenocarcinoma cells and xenografts.
- Analysis of EGFR degradation, MAP kinase signaling, and cytokinesis.
Main Results:
- Activated EGFR phosphorylates SCAMP3 at Y86, enhancing its interaction with EGFR.
- SCAMP3 knockdown promotes lung adenocarcinoma cell survival and tumor growth, indicating a tumor suppressor role.
- SCAMP3 promotes EGFR degradation, attenuates MAP kinase signaling, and is essential for cytokinesis.
- SCAMP3 Y86 phosphorylation is critical for its tumor suppressor functions.
Conclusions:
- SCAMP3 is a novel tumor suppressor in lung cancer.
- SCAMP3 modulates EGFR signaling and cytokinesis, partly through Y86 phosphorylation.
- Targeting SCAMP3-EGFR interactions could offer new therapeutic strategies for lung cancer.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
Abnormal Proliferation
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway